Imaging of Prostate Cancer Using Fluciclovine

PET Clin. 2017 Apr;12(2):145-157. doi: 10.1016/j.cpet.2016.11.005. Epub 2017 Jan 23.

Abstract

Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Despite high disease prevalence, diagnosis and surveillance of the disease with conventional imaging are limited typically because of indolent biology. Functional imaging with advanced molecular techniques improves the ability to detect disease. Amino acids are building blocks of proteins, and intracellular transport of amino acids is upregulated in prostate cancer. This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging.

Keywords: Axumin; CT; FACBC; Fluciclovine; PET; Prostate.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Carboxylic Acids*
  • Cyclobutanes*
  • Drug Approval
  • Humans
  • Lymph Nodes / diagnostic imaging
  • Lymphatic Metastasis
  • Male
  • Multimodal Imaging / methods
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography / methods
  • Postoperative Care
  • Practice Guidelines as Topic
  • Prostatectomy
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / surgery
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed / methods

Substances

  • Carboxylic Acids
  • Cyclobutanes
  • Radiopharmaceuticals
  • fluciclovine F-18